Evaluating a feedback intervention for reducing overuse of pathology test requesting by Australian general practitioners: a factorial cluster randomised controlled trial

Australian Government Department of Health0 个研究点目标入组 5,964 人开始时间: 2022年4月13日最近更新: 2024年1月22日

适应症

试验速览

暂无简介。

•General practitioners (GPs) practising in Australia, who are in the top 10% of GP referrers overall for 10 targeted combinations of pathology tests and in the top 10% of referrers for at least 2 individual test combinations. Targeted combinations of pathology tests are:
•1. Iron studies (66596), TSH (66716) and Vitamin D (66833);
•2. Iron studies (66596), Vitamin D (66833) and Vitamin B12 (66838/66839);
•3. Iron studies (66596), Thyroid Stimulating Hormone (TSH) (66716) and Vitamin B12 (66838/66839);
•4. Iron studies (66596), Thyroid Function Tests (TFT) (66719) and Vitamin B12 (66838/66839);
•5. Iron studies (66596), TFT (66719) and Vitamin D (66833);
•6. TSH (66716) and Vitamin D (66833) and Vitamin B12 (66838/66839);
•7. Iron studies (66596) and Vitamin D (66833);
•8. Iron studies (66596) and Vitamin B12 (66838/66839);
•9. Iron studies (66596) and TFT (66719);
•10. TSH (66716) and Vitamin D (66833).
•Only pathology tests requests that lead to a service being rendered by a pathologist and for which a Medicare Benefits Schedule (MBS) claim is made are in scope.

•1.GPs with <1000 Category 1 services between 1 July 2019 and 30 June 2020, and/or <1000 Category 1 services between 1 July 2020 and 30 June 2021.
•2.GPs who did not make any in-scope pathology test requests within the nominated 24-month period (1 July 2019 to 30 June 2021).
•3.GPs who participated in user testing of the intervention.
•4.GPs who are currently or have been involved in a Department of Health compliance activity commencing on or after 1 May 2021.
•5.GPs with a hospital as their primary practice address.
•6.GPs with a primary practice address in remote or very remote geographical areas (MM6-7).

发起方

Australian Government Department of Health